[{"StockholdersEquityConverted_0_Q1_USD":703435000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":85530000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":124422000.0,"EarningsPerShareDiluted_1_Q1_USD":2.35,"CommonStockSharesOutstanding_0_Q1_shares":85365000.0,"StockholdersEquity_0_Q1_USD":702696000.0,"NetIncomeLossConverted_1_Q1_USD":204289000.0,"RevenuesConverted_1_Q1_USD":777707000.0,"Assets_0_Q1_USD":2327385000.0,"CommonStockSharesConverted_0_Q1_shares":106676000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":86917000.0,"EarningsPerShareBasic_1_Q1_USD":2.39,"Ticker":"IDXX","CIK":"874716","name":"IDEXX LABORATORIES INC \/DE","OfficialName":"IDEXX Laboratories Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"42180715521.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"SP500","filed":"20210504"}]